

WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN: L68100DL1996PLC227773

Registered Office: Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Delhi, New Delhi, Delhi, India, 110092

Email: welcuredrugs227@gmail.com; **Website:** <https://welcure.co.in/>

Date: May 29, 2026

To,
The Listing Department
BSE Limited
Department of Corporate Affairs
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Reference: ISIN- INE331C01025; Scrip Code- 524661; Symbol- WELCURE

Subject: Outcome of the Meeting of the Board of Directors of Welcure Drugs and Pharmaceuticals Limited held today i.e Friday, 29th May 2026.

Dear Sir/Ma'am,

Pursuant to the Regulation 30 and other applicable regulations of the SEBI (Listing obligation & Disclosure requirements) Regulations, 2015 and in continuation of our earlier intimation of the Board Meeting dated 22nd May, 2026 we hereby inform you that meeting of the Board of Directors of the Company, duly convened and held at the registered office of the Company i.e. Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Delhi, New Delhi, Delhi, India, 110092 held today i.e., 29th May 2026 at 05.00 P.M. (i.e., 17:00 Hours) and concluded at 07.00 P.M. (i.e., 19:00 Hours) the Board of Directors has inter alia transacted the following businesses:

1. Audited Standalone Financial Results along with Auditor's Report of the Company for the quarter and year ended March 31, 2026 in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) 2015. Copy of the same is attached herewith for your reference.

Further, pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a declaration that the Statutory Auditors of the Company have issued an Audit Report with an unmodified opinion on the Audited Standalone Financial Results of the Company for the quarter and year ended March 31, 2026, is also attached for your ready reference.

2. Audited Standalone Financial Statements of the Company for the year ended March 31, 2026 along with Auditor's Report thereon in terms of Section 134 of the Companies Act, 2013.

You are requested to please take the same in your record.

Thanking you,
Yours Faithfully,

FOR WELCURE DRUGS AND PHARMACEUTICALS LIMITED

**CHINTAN DIDAWALA GANPAT
MANGING DIRECTOR & CFO
DIN: 11088268**



**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

INDEPENDENT AUDITOR'S REPORT ON AUDITED STANDALONE QUARTERLY FINANCIALS RESULTS AND YEAR TO DATE RESULTS OF WELCURE DRUGS AND PHARMACEUTICALS LIMITED PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

To the Board of Directors of
WELCURE DRUGS AND PHARMACEUTICALS LIMITED

We have audited the accompanying statement of financial results of WELCURE DRUGS AND PHARMACEUTICALS LIMITED (the "Company") for the Quarter and year ended 31st March, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these financial results:

- (a) are presented in accordance with the requirements of regulation 33 of the LODR regulations in this regard and
- (b) give a true and fair view in conformity with the recognition and measurement of principles laid down in the applicable accounting standards and other accounting principles generally accepted in india of the net profit/(loss), other comprehensive income /(expense) and other financial information of the company for the quarter and year ended march 31, 2026.

Basis of Opinion

We have conducted our audit in accordance with the standards on auditing (SAs) specified under section 143 (10) of the companies Act, 2013. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the standalone financial statements section of our report. We are independent of the company in accordance with the code of ethics issued by the institute of chartered accountants of india ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the companies act, 2013 and the rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and ICAI's Code of Ehtics.





**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matters

- We would like to draw attention to the balance of trade receivables and trades payables and loans and advances which are subject to certain uncertainties and for which we have asked the management for email id of concerned parties for external balance confirmation via email . Our audit procedures could not completely verify the accuracy, recoverability or payability of these balances. As such, the final realizable value of trade receivables and the settlement amount of trade payables may differ from the amounts presented in the financial statements. Notwithstanding this matter, our opinion remains unmodified.
- The company has trade payables amounting to Rs 19946.50 , however, the supporting for bifurcation of Micro, Small, and Medium Enterprises (MSME) creditors has not been provided. Non-disclosure of MSME classification contravenes the Micro, Small and Medium Enterprises Development (MSMED) Act, 2006, impacting regulatory compliance and financial transparency.
- Advances to suppliers of ₹15126.13 Lacs remain unconfirmed. Absence of confirmations from these suppliers affects the reliability of liabilities disclosed in the financial statements.
- We are in receipt of certain sales invoices; however, they are not supported with E-Way bills, Delivery Challans, or Transportation details. In the absence of these critical documents, we are unable to verify the genuineness of the transactions.
- The Company has not maintained Goods Inward Reports with respect to purchases, nor does it own or lease any warehouse or godown facility. Management has represented that goods are traded directly from vendors to customers without being stored by the Company. However, in the absence of documentary evidence, we are unable to verify the accuracy of this assertion. Furthermore, inventory as at 31st March 2026 stands at ₹1,43,52.36 Lacs and we were unable to obtain sufficient appropriate audit evidence to confirm the existence and valuation of the same.





**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

Responsibilities of Management and Board of Directors for the Financial Results

The Statement has been prepared on the basis of the annual/quarterly financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.





**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

Auditor's Responsibilities for the Audit of Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.





**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion.

Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The accompanying Statement includes the results for the quarter ended 31st March, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year, which were subject to limited review by us, as required under the Listing Regulations. Our opinion on the Audit of the Financial Results for the year ended 31st March, 2026 is not modified in respect of this matter.

FOR
SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES
CHARTERED ACCOUNTANTS
FRN: 159649W


CA SARANG CHAVAN
(PROPRIETOR)
M.NO.142576
UDIN: 26142576ZPGUVB3176
Date: 29/05/2026
Place: Ahmedabad



WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN :L68100DL1996PLC227773

Regd. Off. : Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Dehli - 110092

Website : www.welcuredrugs.com

Email: welcuredrugs227@gmail.com

STATEMENT OF AUDITED FINANCIAL RESULT FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(Rs in Lacs)

Particulars	Quarter Ended			For The year ended	
	31.03.2026 (Audited)	31.12.2025 (Un-Audited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
Income:					
Revenue from Operations	-	-	2,121.10	36,553.83	2,455.00
Other income	-	146.43	191.10	146.43	190.99
Total income (A)	-	146.43	2,312.19	36,700.26	2,645.99
Expenses:					
Cost of materials consumed				-	-
Purchases of stock-in-trade			14,762.40	32,236.71	16,402.70
Operation and maintenance expenses	-			-	-
Changes in Inventories	-	-	(12,990.90)	-	(14,352.36)
Purchase & Direct Expenses	-	-	-	-	-
Employee benefit expense	-	1.94	25.00	10.36	27.65
Finance costs	-	-	-	-	-
Depreciation & Amortization expenses	-	0.50	0.60	1.91	0.76
Other expenses	4,986.14	1.44	261.00	5,000.29	289.23
Total expenses (B)	4,986.14	3.87	2,058.10	37,249.27	2,367.98
Profit before tax for the year (C) = (A-B)	(4,986.14)	142.56	254.09	(549.01)	278.01
Tax expense:					
(i) Current tax	-	35.88	-	-	61.00
(ii) Deferred Tax Expenses	-	-	-	-	-
Total tax expense (D)	-	35.88	-	-	61.00
Other comprehensive Income (after Tax)					
A) Items that will not be reclassified to profit and loss					
Income Tax on above	-				
B) Items that will be reclassified to profit and loss					
Income tax on above	-				
Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-
Total Comprehensive Income for the period comprising Net Profit/ (Loss) for the period & Other Comprehensive Income	(4,986.14)	106.68	254.09	(549.01)	217.01
Paid-up equity share capital (Face Value: Rs. 1/- each)	12,359.40	12,359.40	1,125.12	12,359.40	1,125.12
Earnings per equity share (in ₹)					
Basic	(0.40)	0.01	0.33	(0.04)	0.36
Diluted	(0.40)	0.01	0.33	(0.04)	0.36

Notes:

- The above Audited financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their respective meeting held on 29th May, 2026.
- The Auditor of the Company has carried out a audit of the Financial Results for the Quarter ended 31st March,2026 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 and has expressed their unqualified opinion.
- The Audited Standalone Financial Results have been prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (IND AS 34), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange board of India (SEBI) under SEBI (LODR) Regulation 2015, as amended.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary.
- The company does not have any Subsidiaries, Joint Ventures or Associate Companies as on March 31,2026

For Welcure Drugs and Pharmaceuticals limited

Place: Delhi
Date: 29/05/2026

Chintan Didawala Ganpat
Managing Director & CFO
DIN : 11088268

Welcure Drugs and Pharmaceuticals Limited

CIN :L68100DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Website: www.welcuredrugs.com

Email: welcuredrugs227@gmail.com

AUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITY AS AT 31-03-2026

(Rupees in Lacs)

Particulars	As at 31st March,2026	As at 31st March, 2025
ASSETS		
Non-current assets		
Property Plant and Equipment	1.11	3.03
Other Intangible assets		
Financial Assets		
Investments	128.74367	
Loans	15126.13	8472.96
Other Financial Assets		
Deferred tax assets (net)		
Non-current Tax Assets (Net)		
Other non-current assets	8.02	7.73
Current assets		
Inventories	14352.36	14352.36
Financial Assets		
Trade receivables	21335.94	1895.00
Cash and cash equivalents	57.62	12.83
Loans		
Other Financial Assets	0	1950.84
Other current assets	9.02	3.08
Total Assets	51018.95	26697.82
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	12359.40	11243.91
Other Equity	(2657.37)	(989.56)
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
Borrowings	0	12319.89
Other Financial Liabilities		
Provisions		
Current liabilities		
Financial Liabilities		
Borrowings		
Trade Payables		
Total outstanding due of		
(A) Micro enterprises and small enterprises	0	2.81
(B) Creditors other than micro enterprises and small enterprises	19946.5	286.95
Other Financial Liabilities	21307.72	3773.51
Other current liabilities	1.68	1.68
Provisions	61	0.93
Current Tax Liabilities (Net)		61.00
Total Equity and Liabilities	51018.95	26701.12

**For, WELCURE DRUGS &
PHARMACEUTICALS LIMITED**

Date: 29/05/2026

Place: Delhi

**Chintan Didawala Ganpat
Managing Director & CFO
DIN : 11088268**

WELCURE DRUGS & PHARMACEUTICALS LIMITED

CIN :L68100DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Website: www.welcuredrugs.com

Email: welcuredrugs227@gmail.com

Statement of Standalone Cash Flow for the Year ended March 31, 2026

Rs in Lakhs

Sr. No.	Particulars	Upto 31st March,2026		F.Y. 2024-25	
		Amount (In Rs.)	Amount (In Rs.)	Amount (In Rs.)	Amount (In Rs.)
A.	<u>Cash flow from Operating Activities</u>				
	Net Profit before taxation	(549.01)			278.01
	Adjustments for :				
	Depreciation & Amortisation Exp.	1.91		0.76	
	Previous Year Taxes Written Off				
	Prior Period Expense				0.76
	Operating Profit before working capital changes		(547.10)		278.77
	Adjustment for				
	Inventory	-		(14,352.36)	
	Trade receivable	(19,440.94)		(1,895.00)	
	Long term loans and advances	(6,653.17)		(8,344.22)	
	Other financial Assets	1,950.84		(1,950.84)	
	Other Current Assets	5.94		(2.06)	
	Trade Payable	19,656.74		289.76	
	Other Non Current Assets	0.29		-	
	Other Financial Liability	(12,319.89)		3,772.41	
	Increase in Short term provision	(13.39)		-	
	Other Current Liability	17,534.21	720.63	0.66	(22,481.65)
	Net Cash Flow from Operating Activities (A)		173.53		(22,202.88)
B.	<u>Cash flow from investing Activities</u>				
	Purchase/ Sale of Fixed Assets	-		(1.70)	
	Change in Investments	128.74		(4.65)	
	Net Cash Flow from Investing Activities (B)		(128.74)		(6.35)
C.	<u>Cash Flow From Financing Activities</u>				
	Proceeds From Issue of Equity Capital	-		9,900.00	
	Repayment of long term borrowing	-			
	Proceeds from long term borrowing			12,319.89	
	Net Cash Flow from Financing Activities (C)		-		22,219.89
D.	Net (Decrease)/ Increase in Cash & Cash Equivalents (A+B+C)		44.79		10.67
E.	Opening Cash & Cash Equivalents		12.83		2.16
F.	Cash and cash equivalents at the end of the period		57.62		12.83

For, WELCURE DRUGS & PHARMACEUTICALS LIMITED

Date: 29/05/2026
Place: Delhi

Chintan Didawala Ganpat
Managing Director & CFO
DIN : 11088268

WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN:L68100DL1996PLC227773

Regd. Off. : Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Dehli - 110092

Website : www.welcuredrugs.com

Email: welcuredrugs227@gmail.com

SEGMENT REPORTING FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

Rs in lakhs

PARTICULARS	NOTES	Quarter Ended			For The year ended	
		31.03.2026 (Audited)	31.12.2025 (Un-Audited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
BUSINESS SEGMENTS INFORMATION						
1. Segment Revenues:						
a. Agriculture		-	146.43	2,312.19	36,700.26	2,645.99
b. Drugs and Pharmaceuticals		0	0	0	0	0
Total Revenue from Operations		-	146.43	2,312.19	36,700.26	2,645.99
2. Segment Operating Results (EBITDA)						
a. Agriculture		(4,986.14)	142.56	254.09	(549.01)	278.01
b. Drugs and Pharmaceuticals		0	0	0	0	0
Total Operating Results (EBITDA)		(4,986.14)	142.56	254.09	(549.01)	278.01
3. Segment Results (PBT)						
a. Agriculture		(4,986.14)	142.56	254.09	(549.01)	278.01
b. Drugs and Pharmaceuticals		0	0	0	0	0
Total Profit Before Tax (PBT)		(4,986.14)	142.56	254.09	(549.01)	278.01
4. Segment Assets :						
a. Agriculture		51018.95	19522.94	26697.82	51018.95	26697.82
b. Drugs and Pharmaceuticals		0	0	0	0	0
Total Assets		51018.95	19522.94	26697.82	51018.95	26697.82
5. Segment Liabilities :						
a. Agriculture		49893.83	7163.54	25572.7	49893.83	25572.7
b. Drugs and Pharmaceuticals		0	0	0	0	0
Total Liabilities		51018.95	19522.94	26697.82	51018.95	26697.82

Date : 29/05/2026

Place : Delhi

By Order of the Board of Directors of
Welcure Drugs & Pharmaceuticals Limited

Chintan Didawala Ganpat
Managing Director
DIN : 11329665

WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN: L68100DL1996PLC227773

Registered Office: Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar,
East

Delhi, New Delhi, Delhi, India, 110092

Email: welcuredrugs227@gmail.com; **Website:** <https://welcure.co.in/>

Date: May 29, 2026

To,
The Listing Department
BSE Limited
Department of Corporate Affairs
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Reference: ISIN- INE331C01025; Scrip Code- 524661; Symbol- WELCURE

Sub: Declaration of Audit Reports with an unmodified opinion

Dear Sir/Ma'am,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that Sarang Shivajirao Chavan and Associates, Chartered Accountants (FRN: 159649W), Statutory Auditors of the Company, have issued Audit Reports with an unmodified opinion on the Audited Standalone Financial Results of the Company for the year ended March 31, 2026.

Kindly take the same on record.

Thanking you,
Yours truly,

FOR WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CHINTAN DIDAWALA GANPAT
MANAGING DIRECTOR & CFO
DIN: 11088268